Transgenic systems in drug discovery: From target identification to humanized mice

Drug Discovery Today

Volumn 7, Issue 8, 2002, Pages 461-470

  Törnell, Jan ^a   Snaith, Michael ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

BIOTECHNOLOGY; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; DRUG TOXICITY; HUMAN; KNOCKOUT MOUSE; NONHUMAN; REVIEW; TRANSGENE; TRANSGENIC ORGANISM; ANIMAL; DISEASE MODEL; DRUG INDUSTRY; GENETICS; METHODOLOGY; MOUSE; PHARMACOLOGY; REPRODUCIBILITY; TRANSGENIC ANIMAL; TRANSGENIC MOUSE;

ANIMAL; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; DRUG INDUSTRY; HUMAN; MICE; MICE, TRANSGENIC; PHARMACOLOGY; REPRODUCIBILITY OF RESULTS; ANIMALS; HUMANS;

EID: 0037088998     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02234-1     Document Type: Review

References (85)

1. Genetic transformation of mouse embryos by microinjection of purified DNA
2. Integration and stable germ line transmission of genes injected into mouse pronuclei
3. Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus
4. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes
5. Animal models of neuroimmune interactions in inflammatory diseases
6. The hallmarks of cancer
7. Developmental roles of platelet-derived growth factors
8. Overview and perspective on the therapy of Alzheimer's disease from a preclinical viewpoint
9. Transgenic mouse models in angiogenesis and cardiovascular disease
10. The application of high-throughput screening to novel lead discovery
11. DNA microarrays in drug discovery and development
12. Genomics, gene expression and DNA arrays
13. Proteomics to study genes and genomes
14. Microarrays: lost in a storm of data?
15. The sequence of the human genome
16. Initial sequencing and analysis of the human genome
17. BRCA1 mutations in primary breast and ovarian carcinomas
18. A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21
19. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group
20. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
21. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
22. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA
23. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
24. Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci
25. A mouse phenome project
26. Correction of deafness in shaker-2 mice by an unconventional myosin in a BAC transgene
27. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior
28. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse
29. Genome-wide, large-scale production of mutant mice by ENU mutagenesis
30. Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter
31. Targeted alpha(1A)-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy
32. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor
33. A promoter that drives transgene expression in cerebellar Purkinje and retinal bipolar neurons
34. Atrial natriuretic factor-SV40 T antigen transgenes produce tumors and cardiac arrhythmias in mice
35. A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development
36. Of mice and men: genetic skin diseases of keratin
37. High level, regulated expression of the chimeric P-enolpyruvate carboxykinase (GTP)-bacterial O6-alkylguanine-DNA alkyltransferase (ada) gene in transgenic mice
38. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen
39. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
40. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter
41. Use of the tetracycline-controlled transcriptional silencer (tTS) to eliminate transgene leak in inducible overexpression transgenic mice
42. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A
43. Inducible and reversible gene expression with the rtTA system for the study of memory
44. Ecdysone-inducible gene expression in mammalian cells and transgenic mice
45. A versatile synthetic dimerizer for the regulation of protein-protein interactions
46. Disruption of Krox-20 results in alteration of rhombomeres 3 and 5 in the developing hindbrain
47. Altered segmental identity and abnormal migration of motor neurons in mice lacking Hoxb-1
48. PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis
49. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
50. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
51. EPS8 and E3B1 transduce signals from Ras to Rac
52. Site-specific recombination: developments and applications
53. An Escherichia coli system for assay of F1p site-specific recombination on substrate plasmids
54. Recombinase-mediated gene activation and site-specific integration in mammalian cells
55. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting
56. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2
57. Inducible gene targeting in mice
58. Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism
59. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice
60. Site- and time-specific gene targeting in the mouse
61. Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes
62. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse
63. A causal role for E-cadherin in the transition from adenoma to carcinoma
64. Reduced expression of neural cell adhesion molecule induces metastatic dissemination of pancreatic beta tumor cells
65. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
66. Essential role for oncogenic Ras in tumour maintenance
67. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells
68. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery
69. The two-receptor model of lipoprotein clearance: tests of the hypothesis in 'knockout' mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins
70. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet
71. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
72. A transgenic mouse expressing human CYP4B1 in the liver
73. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcinogenesis
74. Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
75. Role of CYP2E1 in the hepatotoxicity of acetaminophen
76. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant mice
77. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas
78. Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12-dimethylbenz[a]anthracene
79. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
80. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1
81. Using genetic mutations to study the neural basis of behavior
82. Postnatal lung function and morphology in transgenic mice expressing transforming growth factor-alpha
83. Decreased lung compliance and air trapping in heterozygous SP-B-deficient mice
84. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor